Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 70 HER2-positive Breast Cancer 15 Carcinoma, Non-Small-Cell Lung 6 HER2 Positive Metastatic Breast Cancer 4 Breast Diseases 4 Brain Neoplasms 4 HER2 Positive Breast Cancer 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Salivary Gland Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Solid Tumor 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1

Interventions

pembrolizumab 156 Gemcitabine 140 Capecitabine 123 Paclitaxel 120 Fluorouracil 117 Oxaliplatin 110 Bevacizumab 106 Nivolumab 99 Leucovorin 97 Docetaxel 97 Cisplatin 89 Radiosurgery 88 Irinotecan 87 Carboplatin 85 Cetuximab 72 Cyclophosphamide 71 Magnetic Resonance Spectroscopy 68 Specimen Handling 60 Radiotherapy 60 Trastuzumab 59 Biopsy 59 Ipilimumab 53 Drug Therapy 51 Everolimus 48 Pemetrexed 46 Albumin-Bound Paclitaxel 45 130-nm albumin-bound paclitaxel 44 Doxorubicin 42 Fulvestrant 40 aldesleukin 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × pyrotinib × Clear all

NCT04355858 2022-07-26

MULAN

Fudan University

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡